Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024
Crescent Biopharma has announced its upcoming presentation at the Jefferies London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am EDT. The company will showcase its lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody being developed for solid tumor treatment.
The presentation will be available via live webcast, with a recording accessible for 90 days afterward. This announcement follows Crescent's recent acquisition agreement with GlycoMimetics (NASDAQ: GLYC) in October 2024. Post-merger, the combined entity will operate as Crescent, focusing on advancing precision-engineered biologics for solid tumor treatments.
Crescent Biopharma ha annunciato la sua prossima presentazione al Jefferies London Healthcare Conference il 19 novembre 2024, alle 12:30 GMT/7:30 EDT. L'azienda presenterà il suo programma principale CR-001, un anticorpo bispecifico tetravalente VEGF1 x PD-1 in fase di sviluppo per il trattamento dei tumori solidi.
La presentazione sarà disponibile tramite webcast in diretta, con una registrazione accessibile per 90 giorni successivi. Questo annuncio segue l'accordo di acquisizione recente di Crescent con GlycoMimetics (NASDAQ: GLYC) nell'ottobre 2024. Dopo la fusione, l'entità combinata opererà come Crescent, concentrandosi sullo sviluppo di biologici ingegnerizzati di precisione per i trattamenti dei tumori solidi.
Crescent Biopharma ha anunciado su próxima presentación en la Jefferies London Healthcare Conference el 19 de noviembre de 2024, a las 12:30 GMT/7:30 EDT. La compañía mostrará su programa principal CR-001, un anticuerpo bispecífico tetravalente VEGF1 x PD-1 que se está desarrollando para el tratamiento de tumores sólidos.
La presentación estará disponible a través de una transmisión web en vivo, con una grabación accesible durante 90 días después. Este anuncio sigue al reciente acuerdo de adquisición de Crescent con GlycoMimetics (NASDAQ: GLYC) en octubre de 2024. Después de la fusión, la entidad combinada operará como Crescent, centrándose en el avance de biológicos diseñados con precisión para los tratamientos de tumores sólidos.
Crescent Biopharma는 2024년 11월 19일 GMT 기준 오후 12시 30분/EDT 기준 오전 7시 30분에 Jefferies London Healthcare Conference에서 발표할 예정이라고 발표했습니다. 회사는 고형종양 치료를 위해 개발 중인 CR-001이라는 테트라발런트 VEGF1 x PD-1 이중 특이성 항체의 주요 프로그램을 소개할 것입니다.
발표는 실시간 웹캐스트를 통해 제공되며, 이후 90일 동안 녹화된 내용을 액세스할 수 있습니다. 이 발표는 2024년 10월 GlycoMimetics (NASDAQ: GLYC)와의 최근 인수 계약에 따른 것입니다. 합병 이후, 결합된 기관은 Crescent로 운영되며, 고형종양 치료를 위한 정밀 설계된 생물학의 발전에 집중할 것입니다.
Crescent Biopharma a annoncé sa prochaine présentation à la Jefferies London Healthcare Conference le 19 novembre 2024, à 12h30 GMT/7h30 EDT. La société présentera son programme phare CR-001, un anticorps bispécifique tétravalent VEGF1 x PD-1 en cours de développement pour le traitement des tumeurs solides.
La présentation sera disponible en direct par webdiffusion, avec un enregistrement accessible pendant 90 jours après. Cette annonce fait suite à l'accord récent d'acquisition de Crescent avec GlycoMimetics (NASDAQ: GLYC) en octobre 2024. Après fusion, l'entité combinée opérera sous le nom de Crescent, se concentrant sur le développement de biologiques spécialement conçus pour les traitements des tumeurs solides.
Crescent Biopharma hat seine bevorstehende Präsentation auf der Jefferies London Healthcare Conference am 19. November 2024 um 12:30 GMT/7:30 EST angekündigt. Das Unternehmen wird sein Hauptprogramm CR-001 vorstellen, ein tetravalentes VEGF1 x PD-1 bispezifisches Antikörper, das für die Behandlung von soliden Tumoren entwickelt wird.
Die Präsentation wird über einen Live-Webcast verfügbar sein, mit einer Aufzeichnung, die 90 Tage lang zugänglich ist. Diese Ankündigung folgt auf den kürzlichen Übernahmeantrag von Crescent mit GlycoMimetics (NASDAQ: GLYC) im Oktober 2024. Nach der Fusion wird die kombinierte Einheit als Crescent operieren und sich auf die Weiterentwicklung von präzisions-engineered Biologika für die Behandlung von soliden Tumoren konzentrieren.
- None.
- None.
Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors
A live webcast of the presentation will be available at https://wsw.com/webcast/jeff315/cresc/1987776. An archived recording will be available for 90 days following the event.
In late October, Crescent entered into an acquisition agreement with
About Crescent Biopharma
Crescent Biopharma is a biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors. The company's pipeline of three programs harnesses proven biology to accelerate the path to market for potentially best-in-class therapeutics. For more information, visit www.crescentbiopharma.com.
Media Contact:
Deerfield Group
Lia Dangelico
540-303-0180
lia.dangelico@deerfieldgroup.com
Investor Contact:
Argot Partners
Dawn Schottlandt
212-600-1902
dawn@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/crescent-biopharma-to-present-at-jefferies-london-healthcare-conference-2024-302301827.html
SOURCE Crescent Biopharma
FAQ
When is Crescent Biopharma presenting at the Jefferies London Healthcare Conference 2024?
What is the acquisition status between Crescent Biopharma and GlycoMimetics (GLYC)?
What is Crescent Biopharma's lead program for solid tumor treatment?
How long will the Jefferies Conference presentation webcast be available for viewing?
